HeyJaredShawn Arrajj
- Indexed articles, last 90 days
- 32
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Tavapadon brings novel option to treat Parkinson's disease by focusing on D1/D5 receptors (opens the original)
Read excerpt
Tavapadon, a treatment for Parkinsonâs disease recently approved by the FDA, provides a novel option for healthcare providers by selectively targeting dopamine receptors in the motor pathways of the brain, according to officials with AbbVie. Tavapadon (Juvmo, AbbVie) is the first approved treatment for Parkinsonâs Disease (PD) to selectively target D1/D5 receptors, as opposed to other treatments that target D2/D3 receptors, Healio previously reported. Although many existing treatments for PD
Women's gains in medicine have not translated into clinical trial leadership roles (opens the original)
Read excerpt
CHICAGO â Women are enrolling in medical school and residency programs at increasing rates in the U.S., but that progress has not translated equally to clinical trial leadership, according to a presenter at the 2026 Women in Medicine Summit. Across clinical trials conducted from 2005 through May 2023, women accounted for only about one-third of identifiable clinical trial principal investigators, said Neelum T. Aggarwal, MD, cognitive neurologist and clinical trialist at Rush University Medica
FDA approves Juvmo, first and only D1/D5 receptor agonist for Parkinson's disease (opens the original)
Read excerpt
The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinsonâs disease designed to selectively target D1/D5 receptors, according to officials with AbbVie. Juvmo (tavapadon) has been approved as an oral tablet to be taken once daily with or without levodopa therapy, according to a press release. By targeting D1/D5 receptors, tavapadon offers healthcare providers an alternative to current dopamine agonists that mainly target D2/D3 receptors, according to Roopal Thakk
Researchers receive $1.6M CDC grant to discern pediatric epilepsy prevalence in U.S. (opens the original)
Read excerpt
The CDC has awarded a $1.6 million grant that will be used by researchers to gain a better understanding of the prevalence of pediatric epilepsy in the U.S. Zachary Grinspan, MD, MS, director of the Pediatric Epilepsy Program at Weill Cornell University, and colleagues will use the funding to carry out the Collaboration to Estimate the Pediatric Incidence of Epilepsy, which he said will combine data from eight sources. As of 2022, the CDC estimates that 456,000 children in the U.S. aged 17 years
Social media posts misrepresent utility of Alzheimer's disease blood tests (opens the original)
Read excerpt
Social media posts about blood tests meant to aid in the diagnosis of Alzheimerâs disease often leave out critical information, and many come from accounts with a financial interest, according to researchers. More than one-third of posts portrayed the tests as a useful screening tool for asymptomatic people, which conflicts with current guidelines, said Jenna Smith, PhD, a Helen & Robert Ellis postdoctoral research fellow with the University of Sydney. âThe chance of developing dementia is c
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.